Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
PP21 Examining Clinical Evidence: Incorporation Of...
Journal article

PP21 Examining Clinical Evidence: Incorporation Of Medications For Ultra-Rare Diseases – Descriptive Analysis Of Conitec Reports (2012 to 2022) – Brazil

Abstract

Introduction

The decision-making process for health technology assessment (HTA) in ultra-rare diseases faces a significant challenge for agencies worldwide. This study sought to offer an analytical overview of the clinical evidence outlined in the recommendations of the Brazilian National Committee for Health Technology Incorporation (Conitec) in ultra-rare diseases.

Methods

Authors

Machado-Rugolo J; da Silva Pereira Curado D; Komoda DS; de Andrade LGM; De Sordi MADP; Fonseca AF; de Almeida JTC; Lima SM; Weber SAT; Santos M

Journal

International Journal of Technology Assessment in Health Care, Vol. 40, No. S1, pp. s62–s62

Publisher

Cambridge University Press (CUP)

Publication Date

12 2024

DOI

10.1017/s0266462324001946

ISSN

0266-4623